



The ProlImmune Journey

- 1998** The ProlImmune Company is founded to pioneer research into the relationship between stress and our immune health.
- 2003** Dr. Albert Crum received the first of several patents relating to glutathione and physiologic methods for increasing intercellular GSH.
- 2004** The ProlImmune Company creates Immune Formulation 100[®] to explore the benefits of whey in supporting immune health and GSH.
- 2006** The ProlImmune Company develops the Free-Form Amino Acid Precursor (FFAAP) mixture that would become Immune Formulation 200[®], avoiding potential allergy complications of the large protein whey.
- 2007** American Chemical Society 234th National Conference, Boston, MA. Dr. Crum presents his work on the disulfide bond and the significance of ‘cracking the code’ of the disulfide bond with Immune Formulation 200[®] – “The unique and vital role of the cystine/cysteine coupling and the importance of the sulfhydryl group in detoxifying oxyradicals to preserve cell, gene and immune health.”
- 2007 - 2011** Clinical research at the Charles R. Drew University, UCLA, UC Irvine, and other universities reveal wide ranging benefits of Immune Formulation 200[®] including surpassing NAC in production of Glutathione and Nrf2 activation.
- 2008** The ProlImmune Company begins providing Immune Formulation 200[®] direct to consumers — a revolutionary approach to elevating Glutathione levels in a way that respects our natural physiology.
- 2015** Canadian Patent Office grants patent 2958753, 2963131 and 3081693
- 2016** University research at Georgia State Virology Lab shows that Immune Formulation 200[®] has dramatic antiviral potential.

- 2019** Pubmed.ncbi.nlm.nih.gov “A Novel antiviral inhibits Zika virus while increasing intracellular glutathione biosynthesis in distinct cell culture models” based on the FFAAP composition of Immune Formulation 200[®]
- 2023** European Patent Office (37 countries) awards Dr. Crum patent on “A Composition for use in Treating Hyperlipidemia, Hypercholesterolemia and/or Hypertriglyceridemia via physiologically Synthesized Glutathione” with the glutathione progenitor core synthesis formulation of Immune Formulation 200[®]
- 2022 – present** The ProImmune Company is continuing research on the many key roles of glutathione in our bodies, the importance of oxidative stress and homeostasis in health and disease and benefits that Immune Formulation 200[®] can contribute through respect of our natural physiology. ProImmune Company is dedicated to continuing to provide Immune Formulation 200[®] worldwide in support of immune health including the potential to increase the efficacy and/or decrease side effects of existing drugs.